Usually for a small cap or micro-cap stock to double, it is because of a buyout. A move today in Vermillion, Inc. (NASDAQ: VRML) has the shares up over 100% after the company reported that the American Medical Association (AMA) Current Procedural Terminology Panel voted to approve the company’s application for a Category 1 CPT code for its OVA1® test. The test is designed to help differentiate benign versus malignant ovarian masses.
Vermillion noted that there has been an unmet clinical need for this triage test. The company also noted that it will help streamline claims processing and accelerate further coverage and adoption by private payers. The AMA recently disclosed the new code on its website, which will become effective January 1, 2013.
What is amazing is that the gain of 114% to $2.85 is on 9 million shares. That is about 80-times normal trading volume. Yahoo! Finance also noted that the 52-week trading range is $0.97 to $7.60 and its market cap after this double-plus is still only almost $43 million.
We do not know if the company will use the opportunity to raise capital or not.
100 Million Americans Are Missing This Crucial Retirement Tool
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.